Physician profile
Arseniy Tsapenko
NPI 1962604140
$3,810.88
in general payments reported to CMS, 2019-2025
34 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $288 · 2021: $432 · 2022: $471 · 2023: $628 · 2024: $516 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.13 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $737.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $444.61 | 2019-2025 | Uptravi, Opsumit |
| Insmed, INC. | $305.71 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $256.42 | 2019-2025 | Zerbaxa, Winrevair, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.71 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $216.45 | 2021-2025 | Avycaz, Teflaro |
| Grifols USA, LLC | $210.09 | 2019-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $185.98 | 2019-2025 | Fasenra, Tagrisso, Airsupra |
| Mylan Specialty L.P. | $122.77 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $111.17 | 2024-2025 | Dupixent |
| Breas Medical, INC. | $93.32 | 2025 | Human Design Medical, Vivo 1/2, Clearo |
| United Therapeutics Corporation | $91.79 | 2019-2025 | Tyvaso |
| Genentech USA, INC. | $81.77 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $72.35 | 2021-2023 | Ultomiris |
| Genzyme Corporation | $72.22 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $59.84 | 2022-2024 | Acthar |
| Olympus America INC. | $58.83 | 2019 | |
| Viatris Specialty LLC | $54.86 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $48.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $47.02 | 2020-2024 | Xarelto |
| Inspire Medical Systems, INC. | $35.52 | 2025 | Inspire |
| Pfizer INC. | $31.88 | 2023-2025 | |
| Philips North America LLC | $31.31 | 2020 | |
| Pulmonx Corporation | $24.46 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astellas Pharma US INC | $23.02 | 2019 | |
| Portola Pharmaceuticals, LLC | $22.98 | 2019 | |
| Electromed, INC. | $19.89 | 2023 | Smartvest |
| La Jolla Pharmaceutical Company | $16.98 | 2025 | Giapreza |
| Verona Pharma, INC. | $15.85 | 2025 | Ohtuvayre |
| Baxter Healthcare | $15.59 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $14.78 | 2019 | |
| Gilead Sciences, INC. | $14.75 | 2022 | |
| Ambu INC. | $14.13 | 2022 | |
| Circassia INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arseniy Tsapenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.